Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Ethical Drug Sales Zoom 8.8% in August: Crecon
October 8, 2021
- Otsuka Gets EU Nod for Pediatric Formulation of TB Drug Deltyba
October 7, 2021
- Opdivo Top-Selling Drug in Japan in September: Encise
October 7, 2021
- Takeda Suspends PII Trials of Narcolepsy Drug Hopeful on Safety Concerns
October 7, 2021
- Asahi Kasei Aims for Pharma Sales of 150 Billion Yen by FY2025
October 6, 2021
- Oncolys Aims to Bring Nucleocapsid Inhibitor into Clinic Next Year for COVID-19 Treatment
October 6, 2021
- JCR’s Hurler Syndrome Drug Earns Fast-Track Status in US
October 6, 2021
- Streamline Regulatory Approval Process with Overseas Data: Rakuten Chief
October 5, 2021
- Astellas to Accelerate Drug Discovery by Forming Specialized Small Teams by Modality: CScO
October 5, 2021
- Enhertu Gets Breakthrough Therapy Tag for 2nd Line Breast Cancer
October 5, 2021
- Ferring Rolls Out Ovulation Inducer Rekovelle in Japan
October 5, 2021
- “Human Error” Is to Blame for Contamination of Moderna COVID-19 Vaccines: Report
October 4, 2021
- Sumitomo Dainippon, Otsuka Ink Global Collaboration for 4 Neuropsychiatric Drugs
October 1, 2021
- JCR Hooks Up with Takeda on Global Expansion of Hunter Syndrome Drug
October 1, 2021
- Asahi Kasei Files Antifungal Cresemba in Japan
October 1, 2021
- Santen, Singapore National Eye Centre Team Up on Training Program for Eye Care Providers
October 1, 2021
- Sanofi Files Sakigake-Designated Olipudase Alfa in Japan for Acid Sphingomyelinase Deficiency
October 1, 2021
- Fujifilm, Australian Startup Join Hands for Contract Manufacturing of iPS Cell-Derived Regenerative Medicine Products
October 1, 2021
- Shionogi Chief Expresses Eagerness for COVID-19 Drug Rollout, PII/III to Wrap Up by Year-End
September 30, 2021
- PeptiDream Bags Milestone Payments from Janssen for Licensing Peptide Discovery Platform Technology
September 30, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…